BioWorld

Sep. 19, 2003

Genta Receives Ganite Approval In Cancer-Related Hypercalcemia

Genta Inc. received its first drug approval Thursday when the FDA cleared Ganite for the treatment of cancer-related hypercalcemia that is resistant to hydration. (BioWorld Today) Read More

Memory Signs Roche To $150M Expansion Of CNS Collaboration

454 Life Sciences Secures $20M To Begin Commercial Operations

Conforma Placement Raises $30M For Cancer Therapies

Neurochem Increases IPO Share Amount, Expects To Raise $54M

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Jan 30, 2025.

Today's news in brief

Briefs

BioWorld MedTech briefs for Jan. 30, 2026.

Brain-derived tau in blood predicts stroke severity and outcome

BioWorld Science

Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...

Centessa’s CNT-9982 shows promise for MDD

BioWorld Science

Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...

First-in-class ADC targeting DEM-TXX shows high preclinical efficacy

BioWorld Science

Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...